Objectives: Normal binaural hearing facilitates spatial hearing and therefore many everyday listening tasks, such as understanding speech against a backdrop of competing sounds originating from various locations, and localization of sounds. For stimulation with bone conduction hearing devices (BCD), used to alleviate conductive hearing losses, limited transcranial attenuation results in cross-stimulation so that both cochleae are stimulated from the position of the bone conduction transducer. As such, interaural time and level differences, hallmarks of binaural hearing, are unpredictable at the level of the inner ears. The aim of this study was to compare spatial hearing by unilateral and bilateral BCD stimulation in normal-hearing listeners with simulated bilateral conductive hearing loss.
Design: Bilateral conductive hearing loss was reversibly induced in 25 subjects (mean age = 28.5 years) with air conduction and bone conduction (BC) pure-tone averages across 0.5, 1, 2, and 4 kHz (PTA 4 ) <5 dB HL. The mean (SD) PTA 4 for the simulated conductive hearing loss was 48.2 dB (3.8 dB). Subjects participated in a speech-in-speech task and a horizontal sound localization task in a within-subject repeated measures design (unilateral and bilateral bone conduction stimulation) using Baha 5 clinical sound processors on a softband. For the speech-in-speech task, the main outcome measure was the threshold for 40% correct speech recognition when masking speech and target speech were both colocated (0°) and spatially and symmetrically separated (target 0°, maskers ±30° and ±150°). Spatial release from masking was quantified as the difference between colocated and separated masking and target speech thresholds. For the localization task, the main outcome measure was the overall variance in localization accuracy quantified as an error index (0.0 = perfect performance; 1.0 = random performance). Four stimuli providing various spatial cues were used in the sound localization task.
Results: The bilateral BCD benefit for recognition thresholds of speech in competing speech was statistically significant but small regardless if the masking speech signals were colocated with, or spatially and symmetrically separated from, the target speech. Spatial release from masking was identical for unilateral and bilateral conditions, and significantly different from zero. A distinct bilateral BCD sound localization benefit existed but varied in magnitude across stimuli. The smallest benefit occurred for a low-frequency stimulus (octave-filtered noise, CF = 0.5 kHz), and the largest benefit occurred for unmodulated broadband and narrowband (octave-filtered noise, CF = 4.0 kHz) stimuli. Sound localization by unilateral BCD was poor across stimuli.
Conclusions: Results suggest that the well-known transcranial transmission of BC sound affects bilateral BCD benefits for spatial processing of sound in differing ways. Results further suggest that patients with bilateral conductive hearing loss and BC thresholds within the normal range may benefit from a bilateral fitting of BCD, particularly for horizontal localization of sounds.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592172 | PMC |
http://dx.doi.org/10.1097/AUD.0000000000001234 | DOI Listing |
Alzheimers Dement
December 2024
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: Hearing impairment is identified as a risk factor for dementia. This study aimed to investigate audiometric hearing level in individuals across the clinical spectrum of cognitive impairment, from normal cognition (NC) to mild dementia, encompassing subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
Method: 135 participants were included in this study.
J Otol
October 2024
Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Beijing, China.
The prevalence of unilateral deafness (SSD) or asymmetric hearing loss (AHL) among patients with hearing impairments ranges from 7.2% to 15.0%, indicating a relatively significant proportion.
View Article and Find Full Text PDFCureus
December 2024
Otolaryngology, Yokosuka Kyosai Hospital, Yokosuka, JPN.
Objective We evaluated the outcomes of tympanic membrane regenerative treatment using gelatin sponge, recombinant basic fibroblast growth factor (bFGF), and fibrin glue at Yokosuka Kyosai Hospital. Methodology We enrolled a total of 42 patients with tympanic membrane perforations (TMPs) (44 ears; right:left = 21:23) that were treated using gelatin sponge, recombinant bFGF, and fibrin glue between July 2020 and December 2023 at Yokosuka Kyosai Hospital. TMP closure rates, improvement of hearing level, and complications were retrospectively included in the evaluation items.
View Article and Find Full Text PDFJ Vis Exp
December 2024
Department of Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health;
Single-sided deafness (SSD), where there is severe to profound hearing loss in one ear and normal hearing in the other, is a prevalent auditory condition that significantly impacts the quality of life for those affected. The ability to accurately localize sound sources is crucial for various everyday activities, including speech communication and environmental awareness. In recent years, bone conduction intervention has emerged as a promising solution for patients with SSD, offering a non-invasive alternative to traditional air conduction hearing aids.
View Article and Find Full Text PDFBraz J Otorhinolaryngol
January 2025
Tokushima University Graduate School, Institute of Biomedical Sciences, Department of Otolaryngology-Head and Neck Surgery, Tokushima, Japan.
Objective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma. Biologics are not indicated for EOM; however, because approximately 10% of ECRS cases has concomitant EOM, concomitant EOM improvement has been observed when dupilumab is administered for ECRS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!